Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hua Medicine (Shanghai) Ltd. (HUMDF)
Shanghai, CN
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's disease, and for the management of both late-stage Type 2 and Type 1 Diabetes. Furthermore, Hua Medicine is also progressing mGLUR5, an investigational treatment targeting levodopa-induced dyskinesia in Parkinson's disease. Established in 2011, the company's operations are headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +5.28% | +5.28% | +5.28% | +188.27% | +113.21% | -38.23% | -13.52% | -13.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+87.7% ★ Q4'25: +4,214.8% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+520.0% ★ Q4'25: +41.7% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-17.3% Q4'25: +10.8% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-29.4% Q4'25: -28.9% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-65.4% Q4'25: -145.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.3% Q4'25: +7.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.76× Q4'25: -1.20× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
17.60M
est: 504.83M (-96.5%)
|
76.61M
est: 117.28M (-34.7%)
|
255.89M
est: 315.12M (-18.8%)
|
480.21M
est: 479.24M (+0.2%)
|
913.41M
910.80M – 916.03M
+90.6% YoY
|
1.37B
1.36B – 1.37B
+49.6% YoY
|
1.82B
1.82B – 1.83B
+33.3% YoY
|
2.20B
2.20B – 2.21B
+21.0% YoY
|
| EBITDA |
-168.06M
est: -283.59M (+40.7%)
|
-167.09M
est: -65.88M (-153.6%)
|
-206.95M
est: -128.37M (-61.2%)
|
-109.51M
est: -195.22M (+43.9%)
|
-372.09M
-373.15M – -371.02M
-90.6% YoY
|
-556.69M
-559.36M – -554.02M
-49.6% YoY
|
-741.92M
-744.05M – -739.80M
-33.3% YoY
|
-897.78M
-900.35M – -895.21M
-21.0% YoY
|
| EBIT |
-199.84M
est: -297.24M (+32.8%)
|
-203.33M
est: -69.05M (-194.4%)
|
-241.54M
est: -141.04M (-71.3%)
|
-141.14M
est: -214.49M (+34.2%)
|
-408.81M
-409.98M – -407.64M
-90.6% YoY
|
-611.63M
-614.56M – -608.70M
-49.6% YoY
|
-815.14M
-817.48M – -812.81M
-33.3% YoY
|
-986.38M
-989.21M – -983.56M
-21.0% YoY
|
| Net Income |
-203.77M
est: -303.21M (+32.8%)
|
-211.23M
est: -142.42M (-48.3%)
|
-250.14M
est: -165.48M (-51.2%)
|
1.08B
est: 815.59M (+32.2%)
|
13.08M
13.03M – 13.12M
-98.4% YoY
|
154.25M
153.68M – 154.82M
+1,079.6% YoY
|
372.12M
370.73M – 373.50M
+141.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
145.28M
est: 2.94B (-95.1%)
|
203.90M
est: 683.53M (-70.2%)
|
269.94M
est: 853.30M (-68.4%)
|
272.69M
est: 1.30B (-79.0%)
|
2.47B
2.47B – 2.48B
+90.6% YoY
|
3.70B
3.68B – 3.72B
+49.6% YoY
|
4.93B
4.92B – 4.95B
+33.3% YoY
|
5.97B
5.95B – 5.98B
+21.0% YoY
|
| EPS |
-0.21
est: -0.31 (+32.0%)
|
-0.22
est: -0.15 (-51.6%)
|
-0.25
est: -0.16 (-51.7%)
|
1.12
est: 0.81 (+37.9%)
|
0.01
0.01 – 0.01
-98.4% YoY
|
0.15
0.15 – 0.15
+1,079.6% YoY
|
0.37
0.37 – 0.37
+141.2% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li Chen | Founder, Chief Executive Officer & Executive Director | 2M | — |
| Chien Cheng Lin | Executive Vice President, Chief Strategy Officer & Executive Director | 839.9K | male |
| Yi Zhang | Senior Vice President of Pharma Development, Chief Medical Officer China and Executive Director | 685.8K | — |
| Fuxing Tang | Chief Technology Officer, Vice President of Chemical Manufacturing Control Department and Head of R&D in USA | — | — |
| Wing Yan Yuen FCIS | Company Secretary | — | female |
| Ying Xie | Vice President of Quality Assurance Division & Chief Quality Officer | — | male |
| Au-Yeung Nelly | Company Secretary | — | female |
| Yu Lu | Vice President of Sales & Marketing | — | male |
| Changhong Li | Chief Scientific Officer | — | — |
| Chengde Wang | Head of IR | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HUMDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
